Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320231 | 0.87 | ALDH1A1 (0.57) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL26429235 | 0.85 | SIRT6 (0.57) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3315404 | 0.84 | MAPT (0.72) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL3312550 | 0.84 | ALDH1A1 (0.55) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL23153740 | 0.82 | HTT (0.52) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3313613 | 0.82 | LMNA (0.55) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL22471157 | 0.79 | MAPT (0.57) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL28423347 | 0.79 | MAPT (0.57) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL3313751 | 0.76 | LMNA (0.57) | LMNAMAPTALDH1A1GPR174MEN1 | |
| SCHEMBL2205083 | 0.76 | SIRT6 (0.72) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | LMNA 3341/4885MAPT 2130/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.